A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek powyżej 18 lat
- •Rak piersi z przerzutami, w tym zaawansowany rak piersi, który nie można operować, nowo wykryty rak piersi na zaawansowanym etapie lub powracający rak piersi z przerzutami
- •Pacjent otrzymywał wcześniej lek Trastuzumab Derukstekan
- •Dostępna historia medyczna pacjenta
✗ Disqualifies
- •Niekompletna historia medyczna
- •Ciąża lub karmienie piersią
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Last updated (source)
- December 15, 2025
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation
Moscow, Russia
Trial contact
Elena Artamonova
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.